...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pharmaceutical care. >Carbapenem Utilization in Critically Ill Patients
【24h】

Carbapenem Utilization in Critically Ill Patients

机译：碳青霉烯在重症患者中的使用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Drug Utilization Evaluation (DUE) studies are designed to evaluate and improve the rational use of medications. DUEs have focused on drugs used in high risk patients such as critically ill cases in this study. Carbapenems are beta-lactam type antibiotics with broad-spectrum of activity which cover Gram-positive, Gram-negative and anaerobic bacteria. The heavy use of carbapenems (imipenem or meropenm) could increase the risk of multi-drug resistant (MDR) pathogens.Methods: This study was a prospective and cross sectional study performed at three intensive care units (ICUs) of Shariati hospital, affiliated with Tehran University of Medical Sciences. The study was conducted from April 2012 to May 2013. All of the patients were on imipenem or meropenem as an empiric treatment or based upon microbiology culture results included in the study.Results: Total of 68 patients in three ICU wards evaluated. The most common diagnosis was Central Nervous System (CNS) infections and meningitis (36.8%). The most common microorganism derived from the patient’s specimen was Acinetobacter spp. (28%). Overall initial treatment for thirty five patients (51.4%) was justified versus nineteen cases (27.9%) of unjustified. For 14 patients (20.5%) empiric treatment was justified, but continuation of treatment was unjustified.Conclusion: The result of the study showed that empiric therapy was justified in most cases (72%), but according to the culture results, continuation of treatment in several cases was unjustified (47%).
机译：背景：药物利用评估（DUE）研究旨在评估和改善合理使用药物。在本研究中，DUEs专注于高危患者（如危重病例）中使用的药物。碳青霉烯类是具有广谱活性的β-内酰胺类抗生素，涵盖革兰氏阳性，革兰氏阴性和厌氧菌。大量使用碳青霉烯类药物（亚胺培南或美罗培南）会增加多药耐药性（MDR）病原体的风险。德黑兰医科大学。该研究于2012年4月至2013年5月进行。所有患者均接受亚胺培南或美罗培南作为经验治疗或基于研究中包括的微生物培养结果。结果：在3个ICU病房中评估了68例患者。最常见的诊断是中枢神经系统（CNS）感染和脑膜炎（36.8％）。来自患者标本的最常见微生物是不动杆菌属。 （28％）。合理的初始治疗35例（51.4％），不合理的19例（27.9％）。对于14例患者（20.5％），经验治疗是合理的，但继续治疗是不合理的。结论：研究结果表明，多数情况下经验治疗是合理的（72％），但根据培养结果，可以继续治疗在某些情况下是不合理的（47％）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号